ApyraVax is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens. The first application is a vaccine for Clostridioides difficile infection, a disease that is causing hundreds of thousands of casualties every year and generating huge medical costs.
Technology
MV BioTherapeutics has developed modified microorganisms that have different characteristics and a unique potential in a wide range of Pharma and Animal Health indications
ApyraMed is a live biotherapeutic that has been validated in pre-clinical studies as immune modulator in cancer patients and intestinal dysbiosis.